Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer

Journal of Urology

Volumn 157, Issue 2, 1997, Pages 569-574

  Mcdonnell, Timothy J ^a   Navone, Nora M ^a   Troncoso, Patricia ^a   Pisters, Louis L ^a   Conti, Claudio ^a   Von Eschenbach, Andrew C ^a   Brisbay, Shawn ^a   Logothetis, Christopher J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

androgens; neoplasm metastasis; prostatic neoplasms; protein p53

Indexed keywords

ANDROGEN; PROTEIN BCL 2; PROTEIN P53; SURAMIN;

ADULT; AGED; ARTICLE; BONE MARROW METASTASIS; CANCER HORMONE THERAPY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL ARTICLE; DISEASE COURSE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0031012825     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65204-2     Document Type: Article

References (24)

1. Kyprianou, N., English, F. and Isaacs, J. T.: Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res., 50: 3748, 1990.
2. Hockenbery, D., Nunez, G., Milliman, C., Schreiber, R. D. and Korsmeyer, S. J.: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature, 348: 334, 1990.
3. Hockenbery, D. M., Zutter, M., Hickey, W., Nahm, M. and Korsmeyer, S. J.: Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc. Natl. Acad. Sci., 88: 6961, 1991.
4. McDonnell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C., Chung, L. W., Hsieh, J. T., Tu, S. M. and Campbell, M. L.: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res., 52: 6940, 1992.
5. Colombel, M., Symmans, F., Gil, S., O'Toole, K. M., Chopin, D., Benson, M., Olsson, C. A., Korsmeyer, S. J. and Buttyan, R.: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Amer. J. Path., 143: 390, 1993.
6. Tu, S. M., McConnell, K., Marin, M. C., Campbell, M. L., Fernandez, A., von Eschenbach, A. C. and McDonnell, T. J.: Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells. Cancer Letters, 93: 147, 1995.
7. Navone N. M., Troncoso, P., Pisters, L. L., Goodrow, T. L., Palmer, J. L., Nichols, W. W., von Eschenbach, A. C. and Conti, C. J.: p53 Protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl. Cancer Inst., 85: 1657, 1993.
8. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B. and Fornace, A. J., Jr.: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71: 587, 1992.
9. Yonish-Rouach, E. D., Resnitzky, J., Lotem, L., Sachs, L., Kimchi, A. and Oren, M.: Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature, 352: 345, 1991.
10. Silvestrini, R., Veneroni, S., Daidone, M. G., Bemomo, E., Boracchi, P., Mezetti, M., Di Fronzo, G., Rilke, F. and Veronesi, U.: The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J. Natl. Cancer Inst., 86: 499, 1994.
11. Marin, M. C., Hsu, B., Meyn, R. E., Donehower, L. A., El-Naggar, A. and McDonnell, T. J.: Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis. Oncogene, 9: 3107, 1994.
12. Logothetis, C. J., Samuels, M. L., von Eschenbach, A. C., Trindade, A., Ogden, S., Grant, C. and Johnson, D. E.: Doxorubicin, mitocmycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. J. Clin. Oncol., 1: 368, 1983.
13. Lowe, S. W., Ruley, H. E., Jacks, T. and Housman, D. E.: P53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957, 1993.
14. Zhang, X., Colombel, M., Raffo, A. and Buttyan, R.: Enforced expression of p53 mRNA and protein in the regressing rat ventral prostate gland. Biochem. Biophys. Res. Comm., 198: 1189, 1994.
15. Colombel, M., Olsson, C. A., Ng, P. Y. and Buttyan, R.: Hormone-regulated apoptosis results from reentry of differentiated prostate cells onto a defective cell cycle. Cancer Res., 52: 4313, 1992.
16. Furuya, Y., Lin, X. S., Walsh, J. C., Nelson, W. G. and Isaacs, J. T.: Androgen ablation-induced programmed death of prostate glandular cells does not involve recruitment into a defective cell cycle or p53 induction. Endocrinology, 136: 1898, 1995.
17. Berges, R. R., Furuya, Y., Remington, L., English, H. F., Jacks, T. and Isaacs, J. T.: Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc. Natl. Acad. Sci., 90: 8910, 1993.
18. Colombel, M., Radvanyi, F., Blanche, M., Abbou, C., Buttyan, R., Donehower, L. A., Chopin, D. and Thiery, J. P.: Androgen suppressed apoptosis is modified in p53 deficient mice. Oncogene, 10: 1269, 1995.
19. Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinanen, R., Palmberg, C., Palotie, H., Tammela, T., Isola, J. and Kallioniemi, O. P.: In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genet., 9: 401, 1995.
20. Taplin, M. E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N. and Balk, S. P.: Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. New Engl. J. Med., 332: 1393, 1995.
21. Sartor, O., Cooper, M., Weinberger, M., Headlee, D., Thibault, A., Tompkins, A., Steinberg, S., Figg, W. D., Linehan, W. M. and Myers, C. E.: Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. J. Natl. Cancer. Inst., 86: 222, 1994.
22. Aprikian, A. G., Sarkis, A. S., Fair, W. R., Zhang, Z.-F., Fuks, Z. and Cordon-Cardo, C.: Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J. Urol., 151: 1276, 1994.
23. Sander, C. A., Yano, T., Clark, H. M., Harris, C., Longo, D. L., Jaffe, E. S. and Raffeld, M.: p53 mutation is associated with progression in follicular lymphoma. Blood, 82: 1994, 1993.
24. Miyashita, T., Krajewski, S., Krajewski, M., Wang, H. G., Lin, H. K., Liebermann, D. A., Hoffman, B. and Reed, J. C.: Tumor suppressor p53 is a regulator of bcl-2 and bax in gene expression in vitro and in vivo. Oncogene, 9: 1799, 1994.